Literature DB >> 25946386

Chapter 6 state of the science of pediatric traumatic brain injury: biomarkers and gene association studies.

Karin Reuter-Rice, Julia K Eads, Suzanna Boyce Berndt, Ellen Bennett.   

Abstract

OBJECTIVES: Our objective is to review the most widely used biomarkers and gene studies reported in pediatric traumatic brain injury (TBI) literature, to describe their findings, and to discuss the discoveries and gaps that advance the understanding of brain injury and its associated outcomes. Ultimately, we aim to inform the science for future research priorities. DATA SOURCES: We searched PubMed, MEDLINE, CINAHL, and the Cochrane Database of Systematic Reviews for published English language studies conducted in the last 10 years to identify reviews and completed studies of biomarkers and gene associations in pediatric TBI. Of the 131 biomarker articles, only 16 were specific to pediatric TBI patients, whereas of the gene association studies in children with TBI, only four were included in this review.
CONCLUSION: Biomarker and gene attributes are grossly understudied in pediatric TBI in comparison to adults. Although recent advances recognize the importance of biomarkers in the study of brain injury, the limited number of studies and genomic associations in the injured brain has shown the need for common data elements, larger sample sizes, heterogeneity, and common collection methods that allow for greater understanding of the injured pediatric brain. By building on to the consortium of interprofessional scientists, continued research priorities would lead to improved outcome prediction and treatment strategies for children who experience a TBI. IMPLICATIONS FOR NURSING RESEARCH: Understanding recent advances in biomarker and genomic studies in pediatric TBI is important because these advances may guide future research, collaborations, and interventions. It is also important to ensure that nursing is a part of this evolving science to promote improved outcomes in children with TBIs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25946386      PMCID: PMC4440919          DOI: 10.1891/0739-6686.33.185

Source DB:  PubMed          Journal:  Annu Rev Nurs Res        ISSN: 0739-6686


  58 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum.

Authors:  Douglas D Fraser; Taylor E Close; Keeley L Rose; Roxanne Ward; Martin Mehl; Catherine Farrell; Jacques Lacroix; David Creery; Murray Kesselman; Danica Stanimirovic; James S Hutchison
Journal:  Pediatr Crit Care Med       Date:  2011-05       Impact factor: 3.624

3.  Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents--second edition.

Authors:  Patrick M Kochanek; Nancy Carney; P David Adelson; Stephen Ashwal; Michael J Bell; Susan Bratton; Susan Carson; Randall M Chesnut; Jamshid Ghajar; Brahm Goldstein; Gerald A Grant; Niranjan Kissoon; Kimberly Peterson; Nathan R Selden; Robert C Tasker; Karen A Tong; Monica S Vavilala; Mark S Wainwright; Craig R Warden
Journal:  Pediatr Crit Care Med       Date:  2012-01       Impact factor: 3.624

4.  Increased CSF concentrations of myelin basic protein after TBI in infants and children: absence of significant effect of therapeutic hypothermia.

Authors:  E Su; M J Bell; P M Kochanek; S R Wisniewski; H Bayir; R S B Clark; P D Adelson; E C Tyler-Kabara; K L Janesko-Feldman; R P Berger
Journal:  Neurocrit Care       Date:  2012-12       Impact factor: 3.210

5.  GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome.

Authors:  Linda E Pelinka; Alfred Kroepfl; Martin Leixnering; Walter Buchinger; Andreas Raabe; Heinz Redl
Journal:  J Neurotrauma       Date:  2004-11       Impact factor: 5.269

6.  Urinary S100B concentrations are increased after brain injury in children: A preliminary study.

Authors:  Rachel Pardes Berger; Patrick M Kochanek
Journal:  Pediatr Crit Care Med       Date:  2006-11       Impact factor: 3.624

7.  The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study.

Authors:  G M Teasdale; G D Murray; J A R Nicoll
Journal:  Brain       Date:  2005-07-20       Impact factor: 13.501

8.  Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children.

Authors:  Antonio Chiaretti; Alessia Antonelli; Riccardo Riccardi; Orazio Genovese; Patrizio Pezzotti; Concezio Di Rocco; Luca Tortorolo; Giovanni Piedimonte
Journal:  Eur J Paediatr Neurol       Date:  2007-09-18       Impact factor: 3.140

9.  Apolipoprotein E4 as a predictor of outcomes in pediatric mild traumatic brain injury.

Authors:  Lisa M Moran; H Gerry Taylor; Kalaichelvi Ganesalingam; Julie M Gastier-Foster; Jessica Frick; Barbara Bangert; Ann Dietrich; Kathryn E Nuss; Jerome Rusin; Martha Wright; Keith O Yeates
Journal:  J Neurotrauma       Date:  2009-09       Impact factor: 5.269

Review 10.  Systematic review of clinical research on biomarkers for pediatric traumatic brain injury.

Authors:  Linda Papa; Michelle M Ramia; Jared M Kelly; Stephen S Burks; Artur Pawlowicz; Rachel P Berger
Journal:  J Neurotrauma       Date:  2013-02-15       Impact factor: 5.269

View more
  2 in total

Review 1.  Pediatric Traumatic Brain Injury: An Update on Preclinical Models, Clinical Biomarkers, and the Implications of Cerebrovascular Dysfunction.

Authors:  Divine C Nwafor; Allison L Brichacek; Chase H Foster; Brandon P Lucke-Wold; Ahsan Ali; Mark A Colantonio; Candice M Brown; Rabia Qaiser
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-22

2.  Association between Day-to-Day Pulsatility Index Change and Neurocognitive Outcomes in Pediatric Traumatic Brain Injury.

Authors:  Jeremy Jordan; Sigrid Ladores; Michele Kong; Tedra Smith; Peng Li; Karin Reuter-Rice
Journal:  Neurotrauma Rep       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.